Advertisement


Tony Mok, MD, and Alice Shaw, MD, PhD: Expert Perspectives on ALK Inhibition and Brigatinib

2015 European Cancer Congress

Advertisement

Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of brigatinib CNS activity in patients with ALK-positive non-small cell lung cancer and intracranial metastases (Abstract 3061).



Related Videos

Global Cancer Care

Mary K. Gospodarowicz, MD, on Challenges in Cancer Control

Mary K. Gospodarowicz, MD, of Princess Margaret Hospital, discusses the work of the Global Task Force on Radiotherapy for Cancer Control and its efforts to improve access to vital ...

Lung Cancer

Jean-Charles Soria, MD, PhD, on Results of the Lux Lung 8 Clinical Trial

Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.

Issues in Oncology
Breast Cancer

Matteo Lambertini, MD, on Preserving Women’s Fertility Through Hormonal Therapy

Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast ca...

Skin Cancer

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Final Results of a Phase II Study

Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).

Kidney Cancer

Brian I. Rini, MD, on A Cancer Vaccine for Renal Cell Carcinoma

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving ...

Advertisement

Advertisement



Advertisement